Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 355

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 355
---
 The TuHURA Board of Directors considered this information as a whole and considered overall the information and factors to be favorable to, and in support of, its determinations and recommendation. Among the material information and factors favoring the merger and the other transactions contemplated by the Merger Agreement considered by the TuHURA Board of Directors were the following:

| • |     | The TuHURA Board of Directors’ positive view, based on the scientific, regulatory and technical due diligence conducted by TuHURA’s management and advisors, of Kineta’s immuno-oncology pipeline including KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, which provides a Phase 2 complementary technology with TuHURA’s current portfolio; |

| • |     | The expectation that the Mergers will result in meaningful synergies by combining key assets, capabilities, and intellectual property, as well as ongoing access to world-leading scientific and clinical collaborators, which is expected to deliver long-term value for stockholders; |

| • |     | The TuHURA Board of Directors’ consideration of the strategic fit with KVA12123, Kineta’s VISTA blocking immunotherapy, to continue developing novel technologies to overcome resistance to cancer immunotherapy; |

| • |     | The expectation that TuHURA will have greater expertise as well as intellectual property and technology access, which will allow TuHURA to accelerate product innovation and investment; |

| • |     | The expectation that TuHURA will have an increased product candidate portfolio; |

| • |     | The recommendation of the Mergers by TuHURA’s senior management team; |

215

| • |     | That the TuHURA Share Value is fixed and will not fluctuate in the event that the market price of Kineta Common Stock increases relative to the market price of TuHURA Common Stock between the date of the Merger Agreement and the consummation of the Mergers; |

| • |     | That TuHURA and Kineta are not required to seek any antitrust regulatory authority clearance or approval of the Mergers. |

| • |     | That TuHURA will continue to be led by the current strong, experienced TuHURA management team; and |

| • |     | That there are limited circumstances in which the Kineta Board of Directors may terminate the Merger Agreement or change its recommendation that Kineta stockholders approve the Merger Agreement Proposal, and if the